Limits...
ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells.

Valabrega G, Fagioli F, Corso S, Madon E, Brach del Prever A, Biasin E, Linari A, Aglietta M, Giordano S - Br. J. Cancer (2003)

Bottom Line: High-dose chemotherapy followed by CD34+ leukapheresis rescue may improve these poor results.On the contrary, BSP was expressed at significant levels in 85% of patients.Moreover, 18% of patients showed a strong and significantly positive (seven to 16 times higher than healthy stem cell donors) ErbB2 expression.

View Article: PubMed Central - PubMed

Affiliation: Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, Candiolo, Italy.

ABSTRACT
Osteosarcoma is the most common malignant bone neoplasia occurring in young patients in the first two decades of life, and represents 20% of all primitive malignant bone tumours. At present, treatment of metastatic osteosarcoma is unsatisfactory. High-dose chemotherapy followed by CD34+ leukapheresis rescue may improve these poor results. Neoplastic cells contaminating the apheresis may, however, contribute to relapse. To identify markers suitable for detecting osteosarcoma cells in aphereses we analysed the expression of bone-specific genes (Bone Sialoprotein (BSP) and Osteocalcin) and oncogenes (Met and ErbB2) in 22 patients with metastatic osteosarcoma and six healthy stem cell donors. The expression of these genes in aphereses of patients affected by metastatic osteosarcoma was assessed by RT-PCR and Southern blot analysis. Met and Osteocalcin proved to be not useful markers since they are positive in aphereses of both patients with metastatic osteosarcoma and healthy stem cell donors. On the contrary, BSP was expressed at significant levels in 85% of patients. Moreover, 18% of patients showed a strong and significantly positive (seven to 16 times higher than healthy stem cell donors) ErbB2 expression. In all positive cases, neoplastic tissue also expressed ErbB2. Our data show that ErbB2 can be a useful marker for tumour contamination in aphereses of patients affected by ErbB2-expressing osteosarcomas and that analysis of Bone Sialoprotein expression can be an alternative useful marker.

Show MeSH

Related in: MedlinePlus

(A) cDNA amplification from human osteosarcoma cell lines with oligonucleotides specific for BSP. The size of the amplified fragment is 534 b. Os10, Mos, U2OS, MG63, Sarg: human osteosarcoma cell lines. (B) Schematic representation of the ratio between BSP and GAPDH expression in stem cell donors and in patients (for experimental details see the Materials and Methods section). A–F: stem cell donors; 1–14: patients affected by metastatic osteosarcoma.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2747549&req=5

fig2: (A) cDNA amplification from human osteosarcoma cell lines with oligonucleotides specific for BSP. The size of the amplified fragment is 534 b. Os10, Mos, U2OS, MG63, Sarg: human osteosarcoma cell lines. (B) Schematic representation of the ratio between BSP and GAPDH expression in stem cell donors and in patients (for experimental details see the Materials and Methods section). A–F: stem cell donors; 1–14: patients affected by metastatic osteosarcoma.

Mentions: BSP is an extracellular bone matrix protein that is mainly expressed by osteoblasts. It has also been shown that its expression is increased in prostate carcinomas where it is strongly associated with poor prognosis (Waltregny et al, 1998). We first showed that BSP mRNA is expressed in human osteosarcoma cell lines (Figure 2AFigure 2


ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells.

Valabrega G, Fagioli F, Corso S, Madon E, Brach del Prever A, Biasin E, Linari A, Aglietta M, Giordano S - Br. J. Cancer (2003)

(A) cDNA amplification from human osteosarcoma cell lines with oligonucleotides specific for BSP. The size of the amplified fragment is 534 b. Os10, Mos, U2OS, MG63, Sarg: human osteosarcoma cell lines. (B) Schematic representation of the ratio between BSP and GAPDH expression in stem cell donors and in patients (for experimental details see the Materials and Methods section). A–F: stem cell donors; 1–14: patients affected by metastatic osteosarcoma.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2747549&req=5

fig2: (A) cDNA amplification from human osteosarcoma cell lines with oligonucleotides specific for BSP. The size of the amplified fragment is 534 b. Os10, Mos, U2OS, MG63, Sarg: human osteosarcoma cell lines. (B) Schematic representation of the ratio between BSP and GAPDH expression in stem cell donors and in patients (for experimental details see the Materials and Methods section). A–F: stem cell donors; 1–14: patients affected by metastatic osteosarcoma.
Mentions: BSP is an extracellular bone matrix protein that is mainly expressed by osteoblasts. It has also been shown that its expression is increased in prostate carcinomas where it is strongly associated with poor prognosis (Waltregny et al, 1998). We first showed that BSP mRNA is expressed in human osteosarcoma cell lines (Figure 2AFigure 2

Bottom Line: High-dose chemotherapy followed by CD34+ leukapheresis rescue may improve these poor results.On the contrary, BSP was expressed at significant levels in 85% of patients.Moreover, 18% of patients showed a strong and significantly positive (seven to 16 times higher than healthy stem cell donors) ErbB2 expression.

View Article: PubMed Central - PubMed

Affiliation: Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, Candiolo, Italy.

ABSTRACT
Osteosarcoma is the most common malignant bone neoplasia occurring in young patients in the first two decades of life, and represents 20% of all primitive malignant bone tumours. At present, treatment of metastatic osteosarcoma is unsatisfactory. High-dose chemotherapy followed by CD34+ leukapheresis rescue may improve these poor results. Neoplastic cells contaminating the apheresis may, however, contribute to relapse. To identify markers suitable for detecting osteosarcoma cells in aphereses we analysed the expression of bone-specific genes (Bone Sialoprotein (BSP) and Osteocalcin) and oncogenes (Met and ErbB2) in 22 patients with metastatic osteosarcoma and six healthy stem cell donors. The expression of these genes in aphereses of patients affected by metastatic osteosarcoma was assessed by RT-PCR and Southern blot analysis. Met and Osteocalcin proved to be not useful markers since they are positive in aphereses of both patients with metastatic osteosarcoma and healthy stem cell donors. On the contrary, BSP was expressed at significant levels in 85% of patients. Moreover, 18% of patients showed a strong and significantly positive (seven to 16 times higher than healthy stem cell donors) ErbB2 expression. In all positive cases, neoplastic tissue also expressed ErbB2. Our data show that ErbB2 can be a useful marker for tumour contamination in aphereses of patients affected by ErbB2-expressing osteosarcomas and that analysis of Bone Sialoprotein expression can be an alternative useful marker.

Show MeSH
Related in: MedlinePlus